Immuneering Corporation

Public

Cambridge, MassachusettsHealthcarehttps://www.immuneering.com

Immuneering Corporation is now publicly traded

The data on this page reflects Immuneering Corporation's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Aug 3, 2021

Last Round

Private Placement

Sep 26, 2025

Total Funding Raised

$433.4M

Company Overview

Immuneering (NAS: IMRX) is a biopharmaceutical company dedicated to enhancing patient outcomes in challenging oncologic and neurologic diseases through its advanced computational Disease Cancelling Technology platform and expertise in translational bioinformatics.

Sector

Healthcare

AI Layer

Infrastructure

Keywords

atebimetinib (IMM-1-104)deep cyclic inhibition of the MAPK pathwayoral MEK inhibitor for solid tumorsDisease Canceling Technology (DCT) platformRAS-mutant solid tumor therapycomputational drug discovery platformoral small molecule drugs for cancertranslational bioinformatics for drug discoverycomputational biology services for pharmabiomarker discovery servicesdrug target identification servicespancreatic cancer therapeuticsneurological disease drug development

Immuneering Corporation Comparables

Compare Immuneering Corporation with similar companies based on industry and business-model similarity.

Immuneering Corporation comparables — related companies by embedding similarity
Company	Similarity	Market Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Immuneering Corporation Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Private Placement	Sep 26, 2025
Follow-on Offering	Sep 26, 2025
Private Placement	Aug 26, 2025
IPO	Aug 3, 2021
Series B	Jan 5, 2021
Series A	Oct 4, 2019

View all Funding Rounds

Immuneering Corporation Investors

Notable investors and investment history

Immuneering Corporation investors
Investor	Rounds
Jefferies	IPO
Perceptive Advisors	Series B
Guggenheim Securities	IPO
LYFE Capital	Series B
Morgan Stanley	IPO
T. Rowe Price	Series B
Citadel	Series B

View all Investors

Immuneering Corporation Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Immuneering Corporation Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersCambridge, Massachusetts

Employee Range57

Year Founded2008

Last FundingSep 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.